期刊文献+

Graves病患者血清sCTLA-4测定及临床意义

Expression of sCTLA-4 in Sera from Patients with Graves Disease.
下载PDF
导出
摘要 目的 研究Graves病患者血清中sCTLA—4表达及与甲状腺自身抗体TPO—Ab、TG—Ab和甲状腺激素FT3、FT4相关性在Graves病发病中的作用。方法 以ELISA ABC—HRP法测定sCTLA—4;以ELISA双抗法规定TPO—Ab、TG—Ab;以电化学发光法测定FT3、FT4。结果 实验组sCTLA—4水平与对照组相比明显升高(P<0.01),但与TPO—Ab、TG—Ab相关性不显著(P>0.05,P>0.05),与FT3、FT4亦无明显相关性(P>0.05,P>0.05)。结论 sCTLA—4可能在Graves病的发病机理中发挥重要作用,但作用机制似与甲状腺自身抗体TPO—Ab、TG—Ab及甲状腺激素FT3、FT4无关。 Objective To study the expression of sCTLA-4 and its association with TPO-Ab, TG -Ab, FT3, FT4 in patients with Graves disease. Methods ELISA and ELECSYS were used for the detection of sCTLA- 4, TPO-Ab, TG-Ab and FT3, FT4. Results The level of sCTLA-4 was remarkably increased (P < 0, 01) in sera from patients with Graves disease but significant association of sCTLA -4 with TPO-Ab, TG-Ab, FT3, FT4 was not observed. Conclusions The results suggest that sCTLA-4 may play an important role in Graves disease, but it seems that the effect of sCTLA-4 has no remarkable relation to the TPO-Ab, TG-Ab, FT3, FT4.
出处 《齐齐哈尔医学院学报》 2003年第8期846-846,848,共2页 Journal of Qiqihar Medical University
  • 相关文献

参考文献7

  • 1Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation [J]. Immunity,1994,1:405-413.
  • 2Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infections and autoimmune disease [J]. N Engl J Med, 1996,335:1369-1377.
  • 3Hathcock KS, Laszio G, Pucillo G, et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands:expression and function [J]. J Exp Med, 1994,180 : 631-640.
  • 4Nistico L, Buzzetu R, Pritchard LE, et al. The CTAL-4 gene region of chromosome 2q33 is linked to,and associated with type I diabetes [J]. Hum Mol Genet,1996,5:1075-1080.
  • 5Tivol EA, Boriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 [J]. Immunity, 1995,3:541-547.
  • 6Lee KM, Chuang E, Griffin M, et aL Molecular basis of T cell inactivation by CTLA-4 [J]. Science,1998,282:2263-2266.
  • 7Oaks M K,Hallett K M. cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. [J]. Immunol, 2000, 164(10):5015-5018.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部